Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC.ARWR · Entity 3472 | COO | January 06, 2026 | January 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARROWHEAD PHARMACEUTICALS, INC.
Report date January 06, 2026 · Filed January 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 547,408 |
Last balance in matching sequence
After 2026-01-06 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rowsRow 1 · 2026-01-06 · Gift · Disposed 540 · Balance 474,368 F1: Gift to relatives F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Row 2 · 2026-01-06 · Gift · Disposed 540 · Balance 473,828 F1: Gift to relatives F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Row 3 · 2026-01-06 · Gift · Disposed 540 · Balance 473,288 F1: Gift to relatives F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Row 4 · 2026-01-06 · Gift · Disposed 440 · Balance 472,848 F1: Gift to relatives F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Row 5 · 2026-01-06 · Gift · Disposed 440 · Balance 472,408 F1: Gift to relatives F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Row 6 · 2026-01-06 · Grant · Acquired 75,000 · Balance 547,408 F3: Represents shares underlying restricted stock units which will vest in four equal annual installments. F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Gift to relatives
F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.
F3: Represents shares underlying restricted stock units which will vest in four equal annual installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2022 Filed Jan 8, 2022 01:16 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 4,400 | $63.75 | $280,500.00 |
DisclosureSEC source: 0001209191-22-002599 · doc4.xml · nonDerivative · entry 4 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,191 F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.19 to $64.07, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 05, 2022 Filed Jan 8, 2022 01:16 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 5,000 | $62.49 | $312,450.00 |
DisclosureSEC source: 0001209191-22-002599 · doc4.xml · nonDerivative · entry 3 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,591 F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.09 to $63.02, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 05, 2022 Filed Jan 8, 2022 01:16 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 10,350 | $61.88 | $640,458.00 |
DisclosureSEC source: 0001209191-22-002599 · doc4.xml · nonDerivative · entry 2 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 358,591 F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.08 to $62.03, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 05, 2022 Filed Jan 8, 2022 01:16 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 12,434 | $60.49 | $752,132.66 |
DisclosureSEC source: 0001209191-22-002599 · doc4.xml · nonDerivative · entry 1 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,941 F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.07 to $60.99, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 01, 2022 Filed Jan 5, 2022 02:26 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001308 · doc4.xml · nonDerivative · entry 2 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,375 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| December 31, 2021 Filed Jan 5, 2022 02:26 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy Common Stock) · Derivative | 28,000 | $0.00 Strike: $6.15 | $0.00 |
DisclosureSEC source: 0001209191-22-001308 · doc4.xml · derivative · entry 3 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 28,000 shares Expires 2026-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents the first vesting date. Option vested over four years from date of grant. Read SEC document |
| December 31, 2021 Filed Jan 5, 2022 02:26 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 28,000 | $6.15 | $172,200.00 |
DisclosureSEC source: 0001209191-22-001308 · doc4.xml · nonDerivative · entry 1 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 22:56 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0001209191-21-009368 · doc4.xml · derivative · entry 6 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 90,000 shares Expires 2024-12-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Represents the first vesting date. Option vested over four years from date of grant. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 22:56 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 5,436 | $89.66 | $487,391.76 |
DisclosureSEC source: 0001209191-21-009368 · doc4.xml · nonDerivative · entry 5 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,375 F4 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.45 to $89.85, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 22:56 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 45,348 | $88.88 | $4,030,530.24 |
DisclosureSEC source: 0001209191-21-009368 · doc4.xml · nonDerivative · entry 4 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,811 F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.44 to $89.41, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 22:56 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 31,255 | $88.08 | $2,752,940.40 |
DisclosureSEC source: 0001209191-21-009368 · doc4.xml · nonDerivative · entry 3 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,159 F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.43 to $88.42, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 22:56 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 7,961 | $86.72 | $690,377.92 |
DisclosureSEC source: 0001209191-21-009368 · doc4.xml · nonDerivative · entry 2 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,414 F1 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.26 to $87.11, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 22:56 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 90,000 | $5.22 | $469,800.00 |
DisclosureSEC source: 0001209191-21-009368 · doc4.xml · nonDerivative · entry 1 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2021 Filed Jan 7, 2021 23:11 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 13,243 | $72.67 | $962,368.81 |
DisclosureSEC source: 0001209191-21-002583 · doc4.xml · nonDerivative · entry 3 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,375 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F4 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.63 to $72.79, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 06, 2021 Filed Jan 7, 2021 23:11 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 10,615 | $72.27 | $767,146.05 |
DisclosureSEC source: 0001209191-21-002583 · doc4.xml · nonDerivative · entry 2 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,618 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.62 to $72.62, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 06, 2021 Filed Jan 7, 2021 23:11 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 1,142 | $70.78 | $80,830.76 |
DisclosureSEC source: 0001209191-21-002583 · doc4.xml · nonDerivative · entry 1 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,233 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.78 to $71.42, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 23:27 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-001573 · doc4.xml · nonDerivative · entry 1 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,375 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments. Read SEC document |
| December 04, 2020 Filed Jan 8, 2022 01:16 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002599 · doc4.xml · nonDerivative · entry 6 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,075 Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:33 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 100 | $61.02 | $6,102.00 |
DisclosureSEC source: 0001209191-20-002615 · doc4.xml · nonDerivative · entry 3 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,375 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:33 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 8,931 | $60.43 | $539,700.33 |
DisclosureSEC source: 0001209191-20-002615 · doc4.xml · nonDerivative · entry 2 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,475 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.93 to $60.92, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:33 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 5,594 | $59.61 | $333,458.34 |
DisclosureSEC source: 0001209191-20-002615 · doc4.xml · nonDerivative · entry 1 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,406 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.92 to $59.92, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 23:02 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-001353 · doc4.xml · nonDerivative · entry 1 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments. Read SEC document |
| May 28, 2019 Filed May 29, 2019 23:01 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 30,000 | $24.88 | $746,400.00 |
DisclosureSEC source: 0001209191-19-033296 · doc4.xml · nonDerivative · entry 1 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,000 F1 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $25.02, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 18, 2019 Filed Jan 19, 2019 00:02 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 72,000 | $14.43 | $1,038,960.00 |
DisclosureSEC source: 0001209191-19-004629 · doc4.xml · nonDerivative · entry 1 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,000 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.10 to $14.78, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 00:58 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001485 · doc4.xml · nonDerivative · entry 1 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments. Read SEC document |
| January 01, 2018 Filed Jan 4, 2018 00:31 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-001499 · doc4.xml · nonDerivative · entry 1 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments. Read SEC document |
| January 01, 2017 Filed Jan 5, 2017 01:41 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 145,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-001612 · doc4.xml · nonDerivative · entry 1 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment in January 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.